Floatz logo

WP 1066

Recurrent Brain Neoplasm

M.D. Anderson Cancer CenterSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

62 Active assets in the Recurrent Brain Neoplasm cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 2BBB
Temsirolimus
M.D. Anderson Cancer Center
Phase 2BBB
Sorafenib
National Cancer Institute (NCI)
Phase 2BB
Bxcl501
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB
Nivolumab
InSightec
Phase 3BB

View all 50 →

Same molecule, other indications

WP 1066 is also rated in:

glioblastomaDormant
B
Indicative ·
60 / 100
View asset →
IDH-wildtype glioblastomaDormant
CCC
Indicative ·
53 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →